Phase II evaluation of dalantercept, a soluble recombinant activin receptor-like kinase 1 (ALK1) receptor fusion protein, for the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group Study 0229N Academic Article uri icon

Overview

MeSH Major

  • Activin Receptors, Type II
  • Endometrial Neoplasms
  • Immunoglobulin Fc Fragments
  • Recombinant Fusion Proteins

abstract

  • Dalantercept has insufficient single agent activity in recurrent EMC to warrant further investigation at this dose level and schedule.

publication date

  • January 2015

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC4615687

Digital Object Identifier (DOI)

  • 10.1016/j.ygyno.2015.04.006

PubMed ID

  • 25888978

Additional Document Info

start page

  • 24

end page

  • 9

volume

  • 138

number

  • 1